Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, Gooderham M, Gonzalez ME, Hebert AA, Kircik LH, Lomaga M, Moore A, Papp KA, Prajapati VH, Hanna D, Snyder S, Krupa D, Burnett P, Almaraz E, Higham RC, Chu DH, Berk DR.
JAMA Dermatol. 2024 Nov 1;160(11):1161-1170. doi: 10.1001/jamadermatol.2024.3121.
PMID:39292443
Sunscreens part 2: Regulation and safety.
Abdel Azim S, Bainvoll L, Vecerek N, DeLeo VA, Adler BL.
J Am Acad Dermatol. 2025 Apr;92(4):689-698. doi: 10.1016/j.jaad.2024.02.066. Epub 2024 May 20.
PMID:38777185
Cerebriform eruption related to acute coral dermatitis.
Dyson ME, Kimyai-Asadi A.
Dermatol Online J. 2022 Dec 15;28(6). doi: 10.5070/D328659730.
PMID:36809101
Acute coral contact dermatitis.
Miguel-Gomez L, Fonda-Pascual P.
CMAJ. 2016 Dec 6;188(17-18):1260. doi: 10.1503/cmaj.151370. Epub 2016 Aug 8.
PMID:27503871
Roflumilast foam 0.3% for adolescent and adult patients with seborrheic dermatitis: A randomized, double-blinded, vehicle-controlled, phase 3 trial.
Blauvelt A, Draelos ZD, Stein Gold L, Alonso-Llamazares J, Bhatia N, DuBois J, Forman SB, Gooderham M, Green L, Guenthner ST, Hebert AA, Lain E, Moore AY, Papp KA, Zirwas M, Kato S, Snyder S, Krupa D, Burnett P, Berk DR, Chu DH.
J Am Acad Dermatol. 2024 May;90(5):986-993. doi: 10.1016/j.jaad.2023.12.065. Epub 2024 Jan 20.